🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 690469101
- Market Cap
- Small Cap
- IPO
- 5/4/2017 · $15.00/share
Business: Ovid Therapeutics, Inc. is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Company Contact
- CEO
- Jeremy M. Levin
- CFO
- Timothy Daly
- Headquarters
- 441 Ninth Avenue, 14th Floor, New York, NY 10001
- Phone
- 646-661-7661
- Investor Relations
- Maeve Conneighton, Argot Partners · 917-943-6681 · malexander@ovidrx.com